Lorazepam: Clinical Trials

22 trials of Lorazepam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 2 terminated, 1 withdrawn. 22 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 122Completed 19, Terminated 2, Withdrawn 1
Phase 21Withdrawn 1

Follow Lorazepam: new trials by email Literature Review of Lorazepam trials Research Report on Lorazepam

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg) - Healthy
Phase 1CompletedUniversity Hospital, Basel, Switzerland202024-02-012025-11-17
Psilocybin for Treatment of Obsessive Compulsive Disorder
Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg - Obsessive-compulsive Disorder (OCD)
Phase 1CompletedUniversity of Arizona152019-01-022024-08-30
Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)
Benzodiazepine - limited use strategy, Benzodiazepine - Ad libitum strategy - Post-operative Delirium
Phase 1CompletedMcMaster University4802017-04-012018-10-16
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
LMP744, Ondansetron, Olanzapine - Solid Tumors, Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)362017-02-272024-12-10
Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity
Oxytocin, Lorazepam 1 mg, Placebo nasalspray - Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs
Phase 1CompletedUniversity Hospital, Bonn1202016-03-032019-04-17
Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects
Lorazepam, Placebo - Healthy
Phase 1CompletedPfizer82014-01-012014-03-03
A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
PF-06372865 or Placebo, PF-06372865 or Placebo or Lorazepam - Healthy
Phase 1CompletedPfizer452013-10-012014-08-18
Catatonia in Nodding Syndrome and Lorazepam Treatment
Lorazepam - Catatonia, Nodding Syndrome
Phase 1CompletedMakerere University162013-03-012015-06-03
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
lorazepam - Alzheimer's Disease (AD)
Phase 1CompletedMayo Clinic572013-01-012016-11-10
A Study of the Effect of LY2216684 on Lorazepam
LY2216684, Placebo, Lorazepam - Major Depressive Disorder
Phase 1CompletedEli Lilly and Company282010-12-012019-03-11
EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)
MK3134, Comparator: Lorazepam, Comparator: Placebo - Dementia
Phase 1CompletedMerck Sharp & Dohme LLC252010-06-012015-11-02
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
Lorazepam, AZD7325, Placebo - Recreational CNS Depressant Use
Phase 1CompletedAstraZeneca1002009-05-012009-09-23
How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units
Dexmedetomidine, GABA agonist - Delirium, Respiratory Failure
Phase 1TerminatedVanderbilt University Medical Center62009-01-012017-06-05
A Sedation/Cognition/EEG Study Using AZD6280 and Comparator
AZD6280, Lorazepam, Placebo - Healthy Volunteer
Phase 1CompletedAstraZeneca172008-09-012009-06-26
Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam
Brivaracetam, levetiracetam, lorazepam - Epilepsy
Phase 1CompletedUCB Pharma202008-07-012012-05-28
A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.
AZD7325, Lorazepam - Healthy Volunteer
Phase 1CompletedAstraZeneca162008-06-012010-12-10
A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.
placebo, lorazepam, GW876008 - Healthy Subjects
Phase 1CompletedGlaxoSmithKline262007-03-012010-10-15
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
[123]I-CNS 1261, Lorazepam, Risperidone - Schizophrenia
Phase 1TerminatedGlaxoSmithKline552005-07-012016-01-11
Lorazepam for the Treatment of Status Epilepticus in Children
lorazepam - Status Epilepticus
Phase 1CompletedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)692005-03-012016-05-23
Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg
Lorazepam Tablets 2 mg, Ativan Tablets 2 mg - Healthy
Phase 1CompletedMylan Pharmaceuticals Inc282004-12-012024-04-24

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Alzheimer Disease (1)  ·  Anxiety Disorders (1)  ·  Catatonia (1)  ·  Delirium (1)  ·  Dementia (1)  ·  Depressive Disorder, Major (1)  ·  Dysphonia (1)  ·  Emergence Delirium (1)  ·  Epilepsy (1)  ·  Lymphoma (1)  ·  Nodding Syndrome (1)  ·  Obsessive-Compulsive Disorder (1)  ·  Respiratory Insufficiency (1)  ·  Schizophrenia (1)  ·  Status Epilepticus (1)

Sponsors

AstraZeneca (3)  ·  GlaxoSmithKline (2)  ·  Pfizer (2)  ·  Eli Lilly and Company (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Makerere University (1)  ·  Mayo Clinic (1)  ·  McMaster University (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Mylan Pharmaceuticals Inc (1)  ·  National Cancer Institute (NCI) (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  UCB Pharma (1)  ·  University Hospital, Basel, Switzerland (1)  ·  University Hospital, Bonn (1)

Countries

United States (10)  ·  Netherlands (3)  ·  Canada (2)  ·  Germany (1)  ·  Japan (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Alice P Chen, M.D. (1)  ·  Angelina Kakooza-Mwesige, MMed (1)  ·  Cynthia Stonnington, MD (1)  ·  Dirk M Dhossche, MD, PhD (1)  ·  Dorian Williams, M.D. (1)  ·  Francisco A. Moreno, MD (1)  ·  James Chamberlain, MD (1)  ·  Karen Miotto, M.D. (1)  ·  Myroslava K Romach, MD (1)

Results publications

PMID 17196053, PMID 20887370, PMID 26710961, PMID 29671186, PMID 32416996, PMID 40439882, PMID 41825921

NIH funding

K23DA014291 (1)